Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Nevro (NVRO) Hits New 52-Week High: What's Driving The Stock?

Published 12/25/2019, 10:06 PM
Updated 07/09/2023, 06:31 AM

Shares of Nevro Corp. (NYSE:NVRO) scaled a new 52-week high of $117.51 on Dec 24, closing the session marginally lower at $116.65. In fact, the stock has rallied 36.8% since its third-quarter earnings announcement on Nov 6.

Higher demand for implants, solid U.S. patient trial growth and raised guidance for 2019 prompted the rally.

Let us take a closer look at the factors driving growth.

Robust Q3 Earnings

The company exited the third quarter on a promising note, with narrower loss and higher revenues than the Zacks Consensus Estimate.

In the quarter under review, international revenues were up 5% at constant currency.

U.S. revenues for the quarter also registered a 5% year-over-year uptick. U.S. patient trials and permanent implants each witnessed 18% growth on a year-over-year basis.

Gross profit in the quarter rose 4% year over year.

The lifted revenue outlook for 2019 buoys optimism among investors, indicating the continuation of this bullish trend through the rest of the year.

Other Encouraging Factors

In November 2019, Nevro commercially launched the Senza Omnia Spinal Cord Stimulation System on the heels of attaining the FDA approval for the same. Investors have been optimistic about the company’s growth prospects since the crucial development.

Meanwhile, Nevro has been witnessing a great run on the bourses in the past year. The stock has surged 211.2%, higher than the broader industry’s growth of 22.5%. The company currently has a market cap of $3.62 billion.

Zacks Rank & Stocks to Consider

Nevro currently carries a Zacks Rank #3 (Hold).

A few better-ranked stocks from the broader medical space are Haemonetics Corporation (NYSE:HAE) , NuVasive, Inc (NASDAQ:NUVA) and Omnicell ( (NYSE:OMC) L), each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Haemonetics has a projected long-term earnings growth rate of 13.5%.

NuVasive has an expected long-term earnings growth rate of 10.9%.

Omnicell has a long-term earnings growth rate of 12.5%.

5 Stocks Set to Double

Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>



Omnicom Group Inc. (OMC): Free Stock Analysis Report

Nevro Corp. (NVRO): Free Stock Analysis Report

Haemonetics Corporation (HAE): Free Stock Analysis Report

NuVasive, Inc. (NUVA): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.